Nu-Med Plus Reports Q1 2026 Financial Results with $15,878 Net Loss

Nu-Med Plus, Inc. has reported its financial results for the first quarter of 2026, revealing a net loss of $15,878, a decrease from the net loss of $19,933 recorded in the same period of 2025. The company continues to operate without generating any revenue, maintaining a consistent trend from previous quarters. Operating expenses for the three months ended March 31, 2026, totaled $13,151, down from $18,700 in the prior year, primarily due to reduced professional and consulting fees. The company’s cash position improved to $4,284 from $661 at the end of the previous fiscal year, although total assets decreased to $7,184 from $7,911.

In terms of liabilities, Nu-Med Plus reported total liabilities of $294,340 as of March 31, 2026, compared to $279,189 at the end of 2025. The increase in liabilities is attributed to a rise in accounts payable and related party notes payable. The company’s stockholders' deficit also widened to $287,156 from $271,278, reflecting the ongoing financial challenges faced by the company as it continues to seek funding for its operations and product development.

Strategically, Nu-Med Plus remains focused on the development of its nitric oxide delivery systems, which are still in the early stages and have not yet received FDA approval. The company has suspended product development until it secures additional capital, which it estimates will be approximately $1.2 million over the next twelve months to cover operational and development costs. The company has indicated that it will rely on private stock sales and loans from shareholders to fund its activities, as traditional bank financing is not an option given its current financial state.

Operationally, Nu-Med Plus has not reported any significant changes in customer counts or product adoption rates, as it has yet to bring any products to market. The company continues to explore various applications for nitric oxide in medical treatments, with a focus on reducing delivery costs and expanding its market presence. However, the lack of revenue and ongoing reliance on external funding raise concerns about the company's ability to sustain its operations and execute its business plan.

Looking ahead, Nu-Med Plus acknowledges that its current cash reserves will not be sufficient to support its business plan without additional financing. The company has expressed uncertainty regarding its ability to secure the necessary funding and has highlighted the risks associated with its ongoing product development efforts. As it stands, the company does not anticipate generating revenue in the near future, and its ability to continue operations remains contingent on successful fundraising efforts.